Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies

Trial Profile

Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs Busulfan (Primary) ; Clofarabine (Primary) ; Thiotepa (Primary)
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jan 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.
    • 22 Nov 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 05 Aug 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top